NICE On Alimta, Pixuvri Ups Concerns It Prefers Cost Over Clinical Efficacy

NICE’s tentative nod to CTI’s Pixuvri for NHL and refusal to grant an indication extension to Lilly’s Alimta could spark industry concern that the agency favors lower cost over clinical effectiveness.